NYSE:DVA - Davita Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$57.37 +0.65 (+1.15 %)
(As of 01/21/2019 02:35 PM ET)
Previous Close$56.72
Today's Range$56.88 - $57.73
52-Week Range$48.25 - $79.55
Volume1.30 million shs
Average Volume1.31 million shs
Market Capitalization$9.52 billion
P/E Ratio17.28
Dividend YieldN/A
Beta1.25
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.

Receive DVA News and Ratings via Email

Sign-up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryHealth Care Services
SectorMedical
CUSIP23918K10
Phone303-405-2100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.88 billion
Cash Flow$7.7007 per share
Book Value$26.66 per share

Profitability

Net Income$663.61 million

Miscellaneous

Employees74,500
Market Cap$9.52 billion
OptionableOptionable

Davita (NYSE:DVA) Frequently Asked Questions

What is Davita's stock symbol?

Davita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."

How will Davita's stock buyback program work?

Davita announced that its board has authorized a share buyback program on Wednesday, October 11th 2017, which allows the company to repurchase $1,500,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company's board of directors believes its shares are undervalued.

How were Davita's earnings last quarter?

Davita Inc (NYSE:DVA) released its quarterly earnings results on Wednesday, November, 7th. The company reported $0.56 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.89 by $0.33. The business had revenue of $2.85 billion for the quarter, compared to analysts' expectations of $2.93 billion. Davita had a return on equity of 13.87% and a net margin of 5.39%. The firm's revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the business earned $0.81 EPS. View Davita's Earnings History.

When is Davita's next earnings date?

Davita is scheduled to release their next quarterly earnings announcement on Tuesday, February 12th 2019. View Earnings Estimates for Davita.

What price target have analysts set for DVA?

9 brokers have issued twelve-month target prices for Davita's shares. Their forecasts range from $59.00 to $97.00. On average, they expect Davita's stock price to reach $70.6343 in the next year. This suggests a possible upside of 23.1% from the stock's current price. View Analyst Price Targets for Davita.

What is the consensus analysts' recommendation for Davita?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Davita in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Davita.

Has Davita been receiving favorable news coverage?

Media coverage about DVA stock has been trending positive this week, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Davita earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term.

Who are some of Davita's key competitors?

Who are Davita's key executives?

Davita's management team includes the folowing people:
  • Mr. Kent J. Thiry, Chairman & CEO (Age 62)
  • Joel Ackerman, Chief Financial Officer (Age 53)
  • Mr. James K. Hilger, Chief Accounting Officer (Age 56)
  • Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 50)
  • Mr. Javier J. Rodriguez, Chief Exec. Officer of DaVita Kidney Care (Age 47)

Who are Davita's major shareholders?

Davita's stock is owned by many different of institutional and retail investors. Top institutional investors include Retirement Systems of Alabama (0.09%), Moody National Bank Trust Division (0.05%), State of Alaska Department of Revenue (0.03%), QUANTRES ASSET MANAGEMENT Ltd (0.02%), DNB Asset Management AS (0.01%) and CenturyLink Investment Management Co (0.01%). Company insiders that own Davita stock include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway and William L Roper. View Institutional Ownership Trends for Davita.

Which major investors are selling Davita stock?

DVA stock was sold by a variety of institutional investors in the last quarter, including Coastline Trust Co, Denali Advisors LLC, Louisiana State Employees Retirement System, DNB Asset Management AS, Gateway Investment Advisers LLC and Moody National Bank Trust Division. Company insiders that have sold Davita company stock in the last year include Charles Berg, Pamela M Arway and William L Roper. View Insider Buying and Selling for Davita.

Which major investors are buying Davita stock?

DVA stock was bought by a variety of institutional investors in the last quarter, including QUANTRES ASSET MANAGEMENT Ltd, Trilogy Capital Inc., State of Alaska Department of Revenue, Virtu Financial LLC, Oakbrook Investments LLC, Retirement Systems of Alabama, CenturyLink Investment Management Co and Contravisory Investment Management Inc.. View Insider Buying and Selling for Davita.

How do I buy shares of Davita?

Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Davita's stock price today?

One share of DVA stock can currently be purchased for approximately $57.37.

How big of a company is Davita?

Davita has a market capitalization of $9.52 billion and generates $10.88 billion in revenue each year. The company earns $663.61 million in net income (profit) each year or $3.32 on an earnings per share basis. Davita employs 74,500 workers across the globe.

What is Davita's official website?

The official website for Davita is http://www.davita.com.

How can I contact Davita?

Davita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 303-405-2100 or via email at [email protected]


MarketBeat Community Rating for Davita (NYSE DVA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  384 (Vote Outperform)
Underperform Votes:  419 (Vote Underperform)
Total Votes:  803
MarketBeat's community ratings are surveys of what our community members think about Davita and other stocks. Vote "Outperform" if you believe DVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel